37 results
6-K/A
EX-99.1
SLN
Silence Therapeutics Plc
29 Aug 23
Current report (foreign) (amended)
4:01pm
to withdrawal. No dose limiting toxicity or drug related liver injury was observed. Effects on hepcidin, serum iron, transferrin saturation and hemoglobin
6-K
EX-99.1
SLN
Silence Therapeutics Plc
16 Aug 23
Current report (foreign)
7:00am
to withdrawal. No dose limiting toxicity or drug related liver injury was observed. Effects on hepcidin, serum iron, transferrin saturation and hemoglobin
S-8
EX-99.1
SLN
Silence Therapeutics Plc
1 Aug 23
Registration of securities for employees
4:31pm
not thereafter be altered.
14.2. A Participant who ceases to be an Employee due to:
(a) injury;
(b) disability;
(c) retirement;
(d) Redundancy;
(e
S-8
EX-99.2
8lsapq44ezmwdp we
1 Aug 23
Registration of securities for employees
4:31pm
S-8
EX-99.3
3fcw6t6r9h4dknl
1 Aug 23
Registration of securities for employees
4:31pm
6-K
EX-99.1
se5rxik u6gan
16 May 23
Current report (foreign)
4:01pm
6-K
EX-99.1
b4mplt4mwzdqbjq9dmt
10 Nov 22
Current report (foreign)
8:30am
6-K
EX-99.1
hpeoj2vn2zf9ggo dw
29 Sep 22
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
8:00am
6-K
EX-99.1
tkunm1ncwvlt ameo
16 Nov 21
Current report (foreign)
6:03am
6-K/A
EX-99.1
k2gnfnovylbm5w u6
15 Oct 21
Current report (foreign) (amended)
7:19am
6-K
EX-99.1
9442w gbduteqgc27
12 Aug 21
Current report (foreign)
4:38pm
20-F/A
ljddtk000qfot9
29 Apr 21
Annual report (foreign) (amended)
4:26pm
424B4
jlwktrg5mrj1upx0u
12 Apr 21
Prospectus supplement with pricing info
11:12am
424B4
h5820t
12 Apr 21
Prospectus supplement with pricing info
11:11am
POS AM
b6bpx02rd3ydbhf65
8 Apr 21
Prospectus update (post-effective amendment)
9:31am
POS AM
j0lb9p6o 21hr8euf
8 Apr 21
Prospectus update (post-effective amendment)
9:18am